Capricor Therapeutics (NASDAQ:CAPR) and SkyAI, Inc. Common Stock (NASDAQ:SKYA) Head-To-Head Comparison

Capricor Therapeutics (NASDAQ:CAPR) and SkyAI, Inc. Common Stock (NASDAQ:SKYA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Capricor Therapeutics and SkyAI, Inc. Common Stock, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1	0	9	0	2.80
SkyAI, Inc. Common Stock	1	0	0	0	1.00

Capricor Therapeutics presently has a consensus target price of $48.36, suggesting a potential upside of 74.98%. Given Capricor Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Capricor Therapeutics is more favorable than SkyAI, Inc. Common Stock.

Volatility & Risk

Capricor Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, SkyAI, Inc. Common Stock has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500.

Earnings & Valuation

This table compares Capricor Therapeutics and SkyAI, Inc. Common Stock”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27 million	71.87	-$105.04 million	($2.32)	-11.91
SkyAI, Inc. Common Stock	$200,000.00	274.02	-$282.50 million	($1.63)	-0.79

Capricor Therapeutics has higher revenue and earnings than SkyAI, Inc. Common Stock. Capricor Therapeutics is trading at a lower price-to-earnings ratio than SkyAI, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Capricor Therapeutics and SkyAI, Inc. Common Stock’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-59.27%	-48.65%
SkyAI, Inc. Common Stock	N/A	-157.91%	-154.40%

Insider and Institutional Ownership

21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 17.2% of SkyAI, Inc. Common Stock shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by company insiders. Comparatively, 20.0% of SkyAI, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Capricor Therapeutics beats SkyAI, Inc. Common Stock on 8 of the 13 factors compared between the two stocks.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

About SkyAI, Inc. Common Stock

SkyAI Inc is developing financial technology platforms focused on users in emerging markets. Its operations include the use of stablecoin-based payment infrastructure and artificial intelligence (AI) technologies to provide financial access, educational tools, and data analysis services for users in Asia, Latin America, and Africa. The company’s platform will utilize the Solana blockchain network to support digital asset and on-chain data applications.